Symptomatic atypical femoral fractures are related to underlying hip geometry

Bone

Volumn 63, Issue , 2014, Pages 1-6

  Taormina, David P ^a   Marcano, Alejandro I ^a   Karia, Raj ^a   Egol, Kenneth A ^a,b   Tejwani, Nirmal C ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JAMAICA HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Atypical femur fracture; Bisphosphonate; Hip morphology

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

ACUTE DISEASE; AGED; ANTHROPOMETRIC PARAMETERS; ARTICLE; ASYMPTOMATIC DISEASE; BODY MASS; BONE DISEASE; CASE CONTROL STUDY; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DEMOGRAPHY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FEMUR FRACTURE; FEMUR NECK; FEMUR SHAFT; HIP FRACTURE; HIP RADIOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; RADIOLOGICAL PARAMETERS; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SYMPTOM; TREATMENT DURATION; VARUS DEFORMITY; ANATOMY AND HISTOLOGY; DRUG EFFECTS; FEMORAL FRACTURES; HIP; MIDDLE AGED; REGRESSION ANALYSIS;

AGED; DIPHOSPHONATES; FEMALE; FEMORAL FRACTURES; HIP JOINT; HUMANS; MALE; MIDDLE AGED; REGRESSION ANALYSIS;

EID: 84895764689     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2014.02.006     Document Type: Article

References (37)

1. Johnell O., Kanis J. Epidemiology of osteoporotic fractures. Osteoporos Int 2005, 16:S3-S7.
2. Capeci C.M., Tejwani N.C. Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy. J Bone Joint Surg 2009, 91-A:2556-2561.
3. Lenart B.A., Lorich D.G., Lane J.M. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 2008, 358:1304-1306.
4. Park-Wyllie L.Y., Mamdani M.M., Juurlink D.N., Hawker G.A., Gunraj N., Austin P.C., et al. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. J Am Med Assoc 2011, 305:783-789.
5. Koval K.J., Zuckerman J.D. Fractures in the elderly 1998, 15. Lippincott-Raven Publishers, Philadelphia.
6. Egol K.A., Park J.H., Prensky C., Rosenberg Z.S., Peck V., Tejwani N.C. Surgical treatment improves clinical and functional outcomes for patients who sustain incomplete bisphosphonate-related femur fractures. J Orthop Trauma 2013, 27:331-335.
7. Neviaser A.S., Lane J.M., Lenart B.A., Edobor-Osula F., Lorich D.G. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 2008, 22:346-350.
8. Lenart B.A., Neviaser A.S., Lymann S., Chang C.C., Edobor-Osula F., Steele B., et al. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int 2009, 20:1353-1362.
9. Odvina C.V., Zerwekh J.E., Rao D.S., Maalouf N., Gottschalk F.A., Pak C.Y.C. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005, 90:1294-1301.
10. Armamento-Villareal R., Napoli N., Panwar V., Novack D. Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis. N Engl J Med 2006, 355:2048-2050.
11. Shane E., Burr D., Abrahamsen B., Adler R.A., Brown T.D., Cheung A.M., et al. Atypical subtrochanteric and diaphyseal femoral fractures: Second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2014, 29:1-23.
12. Hollick R., Reid D. Role of bisphosphonates in the management of postmenopausal osteoporosis: an update on recent safety anxieties. Menopause Int 2011, 17:66-72.
13. Shane E., Burr D., Ebeling P.R., Abrahamsen B., Adler R.A., Brown T.D., et al. American Society for B, Mineral R. Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010, 25:2267-2294.
14. Black D.M., Kelly M.P., Genant H.K., Palermo L., Eastell R., Bucci-Rechtweg C., et al. Fracture Intervention Trial Steering C, Committee HPFTS. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 2010, 362:1761-1771.
15. Napoli N., Schwartz A.V., Palermo L., Jin J.J., Wustrack R., Cauley J.A., et al. Risk factors for subtrochanteric and diaphyseal fractures: the study of osteoporotic fractures. J Clin Endocrinol Metab 2013, 98:659-667.
16. Egol K.A., Park J.H., Prensky C., Rosenberg Z.S., Peck V., Tejwani N.C. Surgical treatment improves clinical and functional outcomes for patients who sustain incomplete bisphosphonate-related femur fractures. J Orthop Trauma 2013, 27:331-335.
17. Allison M.B., Markman L., Rosenberg Z., Vieira R.L., Babb J., Tejwani N., et al. Atypical incomplete femoral fractures in asymptomatic patients on long term bisphosphonate therapy. Bone 2013, 55:113-118.
18. Egol K.A., Park J.H., Rosenberg Z.S., Peck V., Tejwani N.C. Healing delayed but generally reliable after bisphosphonate-associated complete femur fractures treated with IM nails. Clin Orthop Relat Res 2013, [Epub (ahead of print)].
19. Marcano A., Taormina D., Egol K.A., Peck V., Tejwani N.C. Are race and sex associated with the occurrence of atypical femoral fractures?. Clin Orthop Relat Res 2014, 472:1020-1027.
20. Rosenberg Z.S., Vieira R.L.R., Chan S.S., Babb J., Akyol Y., Rybak L.D., et al. Bisphosphonate-related complete atypical subtrochanteric femoral fractures: diagnostic utility of radiography. Am J Roentgenol 2011, 197:954-960.
21. Vieira R.L.R., Rosenberg Z.S., Allison M.B., Im S.A., Babb J., Peck V. Frequency of incomplete atypical femoral fractures in asymptomatic patients on long-term bisphosphonate therapy. Am J Roentgenol 2012, 198:1144-1151.
22. Faulkner K.G., Cummings S.R., Black D., Palermo L., Glüer C.-C., Genant H.K. Simple measurement of femoral geometry predicts hip fracture: the study of osteoporotic fractures. J Bone Miner Res 1993, 8:1211-1217.
23. Fredensborg N., The C.E. Angle of normal hips. Acta Orthop 1976, 47:403-405.
24. Ogata K., Goldsand E.M. A simple biplanar method of measuring femoral anteversion and neck-shaft angle. J Bone Joint Surg 1979, 61:846-851.
25. Karanicolas P.J., Bhandari M., Kreder H., Moroni A., Richardson M., Walter S.D., et al. Collaboration for outcome assessment in surgical trials musculoskeletal G. Evaluating agreement: conducting a reliability study. J Bone Joint Surg 2009, 91:99-106.
26. Elbuken F., Baykara M., Ozturk C. Standardisation of the neck-shaft angle and measurement of age-, gender-and BMI-related changes in the femoral neck using DXA. Singapore Med J 2012, 53:587-590.
27. Cermak K., Shumelinsky F., Alexiou J., Gebhart M.J. Case reports: subtrochanteric femoral stress fractures after prolonged alendronate therapy. Clin Orthop Relat Res 2010, 468:1991-1996.
28. Giusti A., Hamdy N.A., Papapoulos S.E. Atypical fractures of the femur and bisphosphonate therapy. A systematic review of case/case series studies. Bone 2010, 47:169-180.
29. Ettinger B., Burr D.B., Ritchie R.O. Proposed pathogenesis for atypical femoral fractures: lessons from materials research. Bone 2013, 55:495-500.
30. Mashiba T., Hirano T., Turner C.H., Forwood M.R., Johnston C.C., Burr D.B. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 2000, 15:613-620.
31. Iwamoto J., Sato Y., Takeda T., Matsumoto H. Hip fracture protection by alendronate treatment in postmenopausal women with osteoporosis: a review of the literature. Clin Interv Aging 2008, 3:483-489.
32. Abrahamsen B., Eiken P., Eastell R. Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis. J Clin Endocrinol Metab 2010, 95:5258-5265.
33. Schilcher J., Michaëlsson K., Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 2011, 364:1728-1737.
34. Gnudi S., Ripamonti C., Gualtieri G., Malavolta N. Geometry of proximal femur in the prediction of hip fracture in osteoporotic women. Br J Radiol 1999, 72:729-733.
35. Gnudi S., Sitta E., Pignotti E. Prediction of incident hip fracture by femoral neck bone mineral density and neck-shaft angle: a 5-year longitudinal study in post-menopausal females. Br J Radiol 2012, 85:e467-e473.
36. Franceschetti P., Bondanelli M., Caruso G., Ambrosio M.R., Lorusso V., Zatelli M.C., et al. Risk factors for development of atypical femoral fractures in patients on long-term oral bisphosphonate therapy. Bone 2013, 56:426-431.
37. Koeppen V.A., Schilcher J., Aspenberg P. Dichotomous location of 160 atypical femoral fractures. Acta Orthop 2013, 84:561-564.